Nothing Special   »   [go: up one dir, main page]

MX2010002392A - Composiciones de brimonidina mejoradas para tratar eritema. - Google Patents

Composiciones de brimonidina mejoradas para tratar eritema.

Info

Publication number
MX2010002392A
MX2010002392A MX2010002392A MX2010002392A MX2010002392A MX 2010002392 A MX2010002392 A MX 2010002392A MX 2010002392 A MX2010002392 A MX 2010002392A MX 2010002392 A MX2010002392 A MX 2010002392A MX 2010002392 A MX2010002392 A MX 2010002392A
Authority
MX
Mexico
Prior art keywords
improved
treating erythema
erythema
brimonidine
compositions
Prior art date
Application number
MX2010002392A
Other languages
English (en)
Inventor
Klaus Theobald
Christopher V Powala
Original Assignee
Galderma Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Lab Inc filed Critical Galderma Lab Inc
Publication of MX2010002392A publication Critical patent/MX2010002392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está dirigida a una composición farmacéutica que incluye tartrato de brimonidina en una cantidad de alrededor de 0.17 a alrededor de 0.19% por peso, en un portador farmacéuticamente aceptable, tal como un gel o una crema eritema en un paciente con rosácea administrando la composición de la invención al sitio del eritema en la piel del paciente.
MX2010002392A 2007-08-31 2008-08-29 Composiciones de brimonidina mejoradas para tratar eritema. MX2010002392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
PCT/US2008/010290 WO2009032223A1 (en) 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema

Publications (1)

Publication Number Publication Date
MX2010002392A true MX2010002392A (es) 2010-07-28

Family

ID=40407909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002392A MX2010002392A (es) 2007-08-31 2008-08-29 Composiciones de brimonidina mejoradas para tratar eritema.

Country Status (12)

Country Link
US (3) US20090061020A1 (es)
EP (1) EP2200617A4 (es)
JP (1) JP2010537988A (es)
KR (1) KR20100055453A (es)
CN (2) CN101808645A (es)
AR (1) AR068816A1 (es)
AU (1) AU2008296948A1 (es)
BR (1) BRPI0816097A2 (es)
CA (1) CA2698680A1 (es)
MX (1) MX2010002392A (es)
NO (1) NO20100301L (es)
WO (1) WO2009032223A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
KR101453601B1 (ko) * 2009-05-29 2014-10-22 갈데르마 리써어치 앤드 디벨로프먼트 주입으로 인한 피부 반응 감소를 위한 필러와 아드레날린 수용체 작용제의 주사가능한 조합
MX2012004890A (es) * 2009-10-26 2012-09-28 Galderma Pharma Sa Metodos para tratar o prevenir eritema agudo.
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
PT2552449T (pt) * 2010-03-26 2017-06-12 Galderma Res & Dev Composições que compreendem brimonidina para o tratamento de eritema
MX2012010823A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
KR101506102B1 (ko) 2010-10-21 2015-03-25 갈데르마 소시에떼아노님 브리모니딘 겔 조성물 및 사용 방법
RU2013123043A (ru) * 2010-10-21 2014-12-10 Галдерма С.А. Гелевая композиция для местного применения
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
ES2742273T3 (es) 2011-02-15 2020-02-13 Aclaris Therapeutics Inc Composiciones de crema farmacéuticas de oximetazolina para tratar los síntomas de la rosácea
US9744168B2 (en) 2011-10-19 2017-08-29 Galderma Laboratories, Inc. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
EP3651767A1 (en) 2017-07-14 2020-05-20 Galderma Research & Development Methods and compositions for reducing side effects in chemotherapeutic treatments
AU2020264808A1 (en) 2019-05-01 2021-11-04 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
WO2009082452A1 (en) * 2007-12-21 2009-07-02 Dejovin Jack A Pre-surgical treatment

Also Published As

Publication number Publication date
US20120040016A1 (en) 2012-02-16
AR068816A1 (es) 2009-12-09
AU2008296948A1 (en) 2009-03-12
CN102552112A (zh) 2012-07-11
US20090061020A1 (en) 2009-03-05
CA2698680A1 (en) 2009-03-12
WO2009032223A1 (en) 2009-03-12
EP2200617A4 (en) 2011-01-12
KR20100055453A (ko) 2010-05-26
US20120282346A1 (en) 2012-11-08
JP2010537988A (ja) 2010-12-09
BRPI0816097A2 (pt) 2016-11-01
EP2200617A1 (en) 2010-06-30
NO20100301L (no) 2010-03-25
CN101808645A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
TN2011000437A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
MY143795A (en) Tetrahydropyridoindole derivatives
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2012002161A (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
AU2016219606A1 (en) Pharmaceutical composition for treating or preventing burn injuries

Legal Events

Date Code Title Description
FA Abandonment or withdrawal